International Society of Hypertension publishes new global hypertension practice guidelines

  • Unger T & al.
  • Hypertension
  • 6 May 2020

  • curated by Emily Willingham, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The International Society of Hypertension has published its first set of guidelines developed to manage hypertension regardless of the population or a region’s resources.
  • The guidelines cover simplified minimum and optimal treatment approaches.

Why this matters

  • The Society says that around 72% of people with hypertension live in low- or middle-income regions.
  • Hypertension is a leading cause of death globally, linked to more than 28,000 deaths daily.
  • The authors of the guidelines say that their intent was to create concise, simplified guidelines that any health care worker could use anywhere around the world.

Key guidance

  • The guidelines cover testing, risk factors, comorbidities, and treatments, including lifestyle modifications and pharmacological treatment.
  • They also address resistant and secondary hypertension and hypertension in pregnancy.
  • The authors define hypertension in 2 grades.
    • The grade 1 hypertension threshold is >140/90 mmHg.
    • The grade 2 hypertension threshold is ≥160/100 mmHg.
  • The guidelines also take race/ethnicity into account.
  • Readers can access 2 versions of simplified treatment flow charts.
    • 1 version covers the minimum standards of care and essential recommendations.
      • Treatment under these guidelines should involve lifestyle interventions for grade 1, along with specialized pharmacological treatment in the case of certain age groups, comorbidities.
      • Under minimum standards, clinicians should “use any drugs available” and try to simplify the regimen with once-a-day dosing and single-pill combination therapies.
    • The other version features the optimal recommendations, or evidence-based standards of care.
      • Where possible, patients with grade 1 should be started on drug treatment concurrently with lifestyle adjustments, and pharmacotherapy should start immediately in patients with diabetes or kidney disease.